Evidence map›Paper›PMID 41170837›Full record

ArticleActa physiologica (Oxford, England)2025

Mitochondrial Dysfunction Contributes to Decompensation in a Zebrafish Model of Isoproterenol-Induced Heart Failure.

Manuel Vicente, Aaron García-Blázquez, Antonio Martínez-Sielva, Jussep Salgado-Almario, Joaquín Jordán, Beatriz Domingo, Juan Llopis

Abstract read
In one paragraph

Article in Acta physiologica (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Multi-Target Cardioprotection fromAntioxidants (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manuel VicentePhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.ORCID https://orcid.org/0000-0002-9464-918X
Aaron García-BlázquezPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
Antonio Martínez-SielvaPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.ORCID https://orcid.org/0000-0002-1337-308X
Jussep Salgado-AlmarioPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
Joaquín JordánPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
Beatriz DomingoPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.ORCID https://orcid.org/0000-0001-9430-4803
Juan LlopisPhysiology and Cell Dynamics, Instituto de Biomedicina de la Universidad de Castilla-La Mancha and Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.ORCID https://orcid.org/0000-0002-9460-0642

Funding

European Regional Development Fund 2022-GRIN-34301Ministerio de Ciencia, Innovación y Universidades PID2022-141928NB-I00Universidad de Castilla-La Mancha
6 · The paper itself

Abstract

aimHeart failure is a clinical syndrome where the heart's structural or functional impairment leads to inadequate blood flow to meet the body's metabolic demands. Mitochondrial dysfunction is increasingly recognized as a central contributor underlying the contractile impairment observed in the failing heart. This study aimed to explore the interplay between calcium dynamics, cardiac mechanical performance, and mitochondrial ATP production during the progression of heart failure in zebrafish larvae exposed to chronic isoproterenol stimulation.

methodsHeart failure was induced by treating zebrafish larvae with 100 μM isoproterenol from 3 to 14 days postfertilization (dpf). Cardiac calcium transients, contractility, and mitochondrial ATP levels were assessed in vivo using transgenic lines expressing specific fluorescent biosensors. Additionally, transcriptomic analysis by RNA sequencing was performed on hearts collected at 14 dpf following prolonged isoproterenol exposure.

resultsAfter 4 days of isoproterenol treatment (7 dpf), larvae exhibited ventricular dilation, reduced calcium levels, and diminished contractile force (p < 0.0001), although cardiac output remained intact. In contrast, extended treatment (11 days; 14 dpf) led to decompensated heart failure, characterized by a significant decline in cardiac output (p < 0.0001). Mitochondrial ATP levels were preserved at 7 dpf but dropped markedly at 14 dpf (p < 0.0001). Transcriptomic profiling at this later stage revealed downregulation of key functions (p < 0.05) involved in mitochondrial energy metabolism and energy transfer.

conclusionIn this model, heart dysfunction was initially evidenced by cardiac dilation. At 4 days of isoproterenol treatment, calcium levels and contractility decreased. Subsequently, decompensation coincided with a collapse in mitochondrial ATP production.

Indexed as

Heart FailureIsoproterenolMitochondria, HeartAdenosine TriphosphateAnimalsAnimals, Genetically ModifiedCalciumDisease Models, AnimalMyocardial ContractionZebrafishAdenosine TriphosphateCalciumIsoproterenolATPcalciumheart failuremitochondriatranscriptomicszebrafish

Identifiers

PMID41170837
PMCPMC12576923

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.